• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

5-Methyl-L-norleucine Orlistat Analogue (CAS 1356847-30-7): A Comprehensive Overview

The 5-Methyl-L-norleucine Orlistat Analogue (CAS 1356847-30-7) is a specialized compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. As an analogue of Orlistat, a well-known lipase inhibitor, this molecule offers unique structural and functional properties that make it a subject of interest for researchers and industry professionals alike. In this article, we delve into the chemical characteristics, potential applications, and market trends surrounding this compound, while also addressing some of the most frequently searched questions in the field.

Chemically, 5-Methyl-L-norleucine Orlistat Analogue is a modified amino acid derivative. Its structure incorporates a 5-methyl group on the L-norleucine backbone, which is a key feature differentiating it from its parent compound, Orlistat. This modification can influence the molecule's binding affinity, metabolic stability, and overall pharmacokinetic profile. Researchers are particularly interested in how these structural changes might enhance or alter the compound's biological activity, especially in the context of enzyme inhibition.

One of the most searched topics related to this compound is its potential role in weight management and metabolic disorders. Given that Orlistat is an FDA-approved drug for obesity treatment, its analogues, including 5-Methyl-L-norleucine Orlistat Analogue, are often explored for similar or improved therapeutic effects. Recent studies have investigated whether this analogue could offer better efficacy or fewer side effects compared to the original drug, making it a hot topic in pharmaceutical research.

Another area of interest is the compound's application in enzyme inhibition studies. Lipases, the primary targets of Orlistat, play crucial roles in fat metabolism. By studying analogues like 5-Methyl-L-norleucine Orlistat Analogue, scientists aim to develop more selective or potent inhibitors that could be used not only for weight management but also for treating conditions like hyperlipidemia and type 2 diabetes. These applications align with current trends in precision medicine and personalized therapies, which are highly searched topics in both academic and public domains.

The synthesis and production of 5-Methyl-L-norleucine Orlistat Analogue also attract considerable attention. Researchers and manufacturers are keen on optimizing synthetic routes to improve yield, purity, and cost-effectiveness. Questions about the compound's stability, solubility, and scalability are frequently searched, reflecting the practical challenges faced in bringing such specialized molecules to market. Advances in green chemistry and sustainable synthesis are often discussed in this context, as the industry moves toward more environmentally friendly practices.

Market dynamics for 5-Methyl-L-norleucine Orlistat Analogue are shaped by the growing demand for novel therapeutic agents and research tools. Pharmaceutical companies and academic institutions are the primary consumers, using the compound for drug discovery and development. The rise of biotech startups and contract research organizations (CROs) has further fueled interest in such specialized molecules, as they often serve as building blocks for more complex drug candidates.

In terms of safety and regulatory considerations, 5-Methyl-L-norleucine Orlistat Analogue is generally regarded as a research chemical with no widespread commercial use outside of laboratories. However, it is essential to handle it with care, adhering to standard laboratory safety protocols. Questions about its toxicity, handling precautions, and storage conditions are common among researchers, highlighting the need for clear and accessible safety data.

Looking ahead, the future of 5-Methyl-L-norleucine Orlistat Analogue appears promising. With ongoing research into its mechanisms of action and potential applications, this compound could play a pivotal role in the development of next-generation enzyme inhibitors and metabolic modulators. Its relevance to current health trends, such as the fight against obesity and metabolic syndrome, ensures that it remains a topic of interest for years to come.

In summary, 5-Methyl-L-norleucine Orlistat Analogue (CAS 1356847-30-7) is a fascinating compound with significant potential in both research and therapeutic applications. Its unique structural features, combined with the growing demand for innovative solutions in metabolic health, make it a standout subject in the chemical and pharmaceutical communities. Whether you're a researcher, a student, or an industry professional, understanding this compound's properties and applications can provide valuable insights into the evolving landscape of medicinal chemistry.

• 130793-27-0(N-Formyl-L-leucine (3S,4R,6S)-3-Hexyltetrahydro-2-oxo-6-undecyl-2H-pyran-4-yl Ester)
• 111466-61-6((S,R,R,R)-Orlistat)
• 111466-62-7((S,S,R,R)-Orlistat)
• 111466-63-8((S,R,S,S)-Orlistat)
• 96829-58-2(Orlistat)
• 686744-60-5(Orlistat Tetradecyl Ester)
• 104872-28-8((R,S,S,S)-Orlistat)
• 113276-96-3(L-Valine, N-formyl-,(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]hexyl ester)
• 1243011-56-4(Octyl Orlistat)
• 1225451-00-2((R,R,S,S)-Orlistat)